DrugPatentWatch Database Preview
Details for Patent: 9,233,118
Which drugs does patent 9,233,118 protect, and when does it expire?
This patent has twenty-nine patent family members in thirteen countries.
Summary for Patent: 9,233,118
Title: | Treatment of papulopustular rosacea with ivermectin |
Abstract: | Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments. |
Inventor(s): | Jacovella; Jean (Antibes, FR), Chappuis; Jean-Paul (Valbonne, FR), Kaoukhov; Alexandre (Newport Beach, CA), Graeber; Michael (Lawrenceville, NJ), Poncet; Michel (Mougins, FR), Briantais; Philippe (Antibes, FR), Salin; Laurence (La Roquette sur Siagne, FR) |
Assignee: | Galderma S.A. (Cham, CH) |
Application Number: | 14/209,958 |
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 9,233,118
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,233,118
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
9,782,425 | Treatment of papulopustular rosacea with ivermectin | ➤ Sign Up |
9,089,587 | Treatment of papulopustular rosacea with ivermectin | ➤ Sign Up |
9,233,117 | Treatment of inflammatory lesions of rosacea with ivermectin | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 9,233,118
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2014287408 | ➤ Sign Up | |||
Australia | 2014287422 | ➤ Sign Up | |||
Canada | 2916668 | ➤ Sign Up | |||
Canada | 2916704 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |